Latest filing published 02 Jul 2025 for SpringWorks Therapeutics, Inc.. Read the official filing
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Daniel Lynch is a declared insider at 3 companies (board member); the most frequent names are SpringWorks Therapeutics, Inc., 2seventy bio, Inc. and bluebird bio, Inc. The record holds 14 filings, for trades running from 20 May 2021 to 1 July 2025.
No open-market purchase appears, only 3 sales worth €6.2M. Outside the open market, there are 9 share grants. Since January 2025: no purchases and 3 sales on the market.
The newest entry dates from 2 July 2025: a transaction, in SpringWorks Therapeutics, Inc. Typically, a trade is published a median of 2 days after it takes place. US insiders must file a Form 4 within two business days of a trade. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
14 of 14 declarations